Transforming Hypertension Management: Trenna’s Journey with Renal Denervation at MCI
High blood pressure, or hypertension, affects millions worldwide, posing significant health risks such as heart attacks, stroke, and kidney disease. Despite medication and lifestyle changes, many struggle to manage their blood pressure effectively. However, a groundbreaking solution known as the Symplicity Spyral™ Renal Denervation (RDN) procedure, is now an option for patients. MCI is proud to offer this treatment option and provide hope for those with resistant hypertension.
Trenna Townsend, a patient of MCI interventional cardiologist Dr. Mark Goodwin, was one of the first patients to undergo the procedure at MCI. Before the procedure, she battled fatigue and high blood pressure, but Dr. Goodwin’s recommendation offered hope. Trenna’s post-procedure experience has been transformative, with increased energy and decreased headaches. Her advice to others considering the procedure is overwhelmingly positive, and she states, “Do it – it saved my life.” Trenna expresses her gratitude that she can now get back to doing what she loves – dancing and spending time with her family.
Dr. Goodwin elaborates, “This is for patients with resistant hypertension, who require multiple medications. It’s done as an outpatient procedure, with patients going home the same day.”
The Symplicity Spyral™ RDN procedure targets overactive nerves near the kidneys, which play a crucial role in blood pressure regulation. Administered under sedation, this minimally-invasive technique involves inserting a thin tube into the artery leading to the kidney. Through ablation, excess nerve activity is calmed, leading to reduced blood pressure without the need for implants.
The Symplicity Spyral™ RDN procedure represents a shift in hypertension management. Dr. Goodwin envisions broader applications, especially for patients unable to tolerate medications. Studies continue to explore its efficacy, with the goal of improving outcomes and reducing healthcare costs.